3B Blackbio DX Ltd — Q3 FY26
3B Blackbio reported 9-month revenue of ₹99.06 crore, up 11.8% YoY (or ~20% excluding seasonal flu spikes).
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
73%Questions answered1Evaded / deflected11Questions auditedMixedNumbers vs filing
Answered
Low priority
Clarification on open vs closed system and new products
Asked by Sagar Tana, Alchemy Ventures
Management directly clarified the terminology without evasion.
Read the exchange
Question
You mentioned that we are in the reagent business and not in the open or closed systems. Is that correct?
Management (unidentified)
No, no, no, no. See, you see when we say open system, we mean reagent. So, you know, we we are supplying kits. So, we consider it as a reagent or you can say that we are into the open kits market to be very precise.
Partial answer
Medium priority
Thoughts on closed system to keep competition away
Asked by Sagar Tana, Alchemy Ventures
Management described their own developments but did not directly answer about closed systems.
did not directly address closed system
Read the exchange
Question
Is there any new kids especially when we see some of your peers who are large and sizable maybe they may be doing just couple of segments but they are in a close system that helps kind of keep competition away any thoughts in terms of newer products newer segments or you know getting into close system kind of kicks.
Management (unidentified)
No so we are already doing a sample to answer machine uh which is a segment by itself. So we are also developing automated extraction. We are trying to develop kits you know which are highly multiplex like our spirit panel AMR panel.
Answered
Medium priority
How UK acquisition helps with products and synergies
Asked by Sagar Tana, Alchemy Ventures
Management explained the purpose and benefits of the UK acquisition directly.
Read the exchange
Question
And s my second question is on our UK acquisition. How is that helping us both in terms of newer products, technologies, etc. And how do we synergize both India versus the UK?
Management (unidentified)
All right. So, first let me clear, we acquired our UK distributor who was already selling our kits in UK. The object was to have those profits which a distributor was having come into the company and to have a subsidiary established in Europe specifically in UK.
Answered
Medium priority
Synergies between India and Belgium operations
Asked by Sagar Tana, Alchemy Ventures
Management clearly stated no synergies yet and explained the current approach.
Read the exchange
Question
And are we able to synergize uh the India versus Belgium operations in terms of technology transfer or anything else?
Management (unidentified)
No. So just now because it is a recent acquisition, we are trying to make them work on a standalone basis. We are integrated. We were earlier also selling the products that they were doing.
Answered
High priority
Cost and timeline for US FDA approvals
Asked by Sagar Tana, Alchemy Ventures
Management provided cost range and timeline directly.
Read the exchange
Question
And sir what would be the cost for the US FDA uh approvals etc. It would be somewhere between say 100,000 USD approximately to 400 maybe and how long would it take for the approvals etc to come through and penetrate those markets start uh distributing in those markets
Management (unidentified)
regulatory approvals take one to two years the moment you have the approval then you start peditating the market which is a process by itself So again to have the full effect come into the company it should be I think maybe 3 or 4 years from now.
Answered
High priority
Reason for increased competitive intensity now
Asked by Ganesh, Danlakshmi Investment
Management directly attributed competition to high margins in molecular diagnostics.
Read the exchange
Question
I just wanted to know for the past 1 year or more than that we have been calling out increase in competition. So what may be the reason for competitive intensity to increase now?
Management (unidentified)
I think this is a very basic question any industry which has a high margin it will have competition if you just see mobile industry where it was and where it is today so new players keep coming
Partial answer
Medium priority
Change in credit periods and metrics to avoid bad receivables
Asked by Ganesh, Danlakshmi Investment
Management described industry norms but did not provide specific metrics or changes.
no specific metrics given
Read the exchange
Question
with respect to the change in credit periods that you are now giving uh so what what would be the change per say uh right now with respect to what you were giving earlier and what are the uh associate associated question would be like what are the metrics that you use that uh to use to ensure that receivables don't go bad
Management (unidentified)
So nowadays our industry easily people are taking 3 to four months and they spill spill overs up to 5 months because lot of suppliers goes to government and the pro there the time taking process. Labs also try to take advantage of long credit cycle and competitors offer the same finance.
Answered
High priority
One-off revenue from HAT contract and its recurrence
Asked by DHL Sha, Dalmas Capital Management
Management provided the one-off revenue amount directly.
Read the exchange
Question
You mentioned 24 crores is what the revenue is for K is for the quarter of this. How much would be the oneoff revenue in the oneoff means the the hat contract?
Management (unidentified)
Yeah, the head contract the government it was 850 850 850k. So if you multiply that with 104 roughly around 8 crores also roughly around 8 crores then yeah 8.8 crores that is the one off.
Evasive
Medium priority
Growth trends in domestic business and industry
Asked by DHL Sha, Dalmas Capital Management
Management declined to answer on quarterly trends, preferring annual view.
refused to comment on quarterly trend
Read the exchange
Question
are you seeing a trend where every quarter gone by the growth rates at least in the domestic business is coming down for the industry
Management (unidentified)
I will not I will not go by quarter on quarter it's a very very because we have seasonal diseases so one quarter will be affected other won't I I would prefer to go it on a a yearly basis and a half yearly basis.
Partial answer
Medium priority
Avenues to venture into other related businesses
Asked by DHL Sha, Dalmas Capital Management
Management said exploring but gave no concrete plans beyond diagnostics.
no specific new segments mentioned
Read the exchange
Question
are there not any areas where we can venture into any existing segments because I mean you mentioned getting into newer technologies but again those are focused again on infections and oncology. So apart from this are there any avenues to get into some other related business?
Management (unidentified)
we are exploring but we will keep focus on the diagnostic segments only because that's where is our experience and uh we will look for other acquisitions if if they give a better product we will take them into Indian market
Answered
High priority
Scope of renewing HAT contract or replacing revenue
Asked by Raja Narula, Individual Investor
Management directly addressed the contract timeline and replacement via US FDA.
Read the exchange
Question
Is there any uh scope of renewing that contract with the government or is there a plan then to replace that revenue once the contract ends?
Management (unidentified)
So I already answered this you know that for next two years uh at 1.5 million it should continue till that 6 billion is finished in parallel we have already started the US FDO work so most probably in one or maybe less than one and a half years we should have the US FDA work
Partial answer
High priority
Current cash position post chorus deal
Asked by Rani Singh, Luama Wealth and Investment Limited
Management gave a rough estimate but not the exact figure.
exact number not given
Read the exchange
Question
what would be the current cash position post that chorus uh deal?
Management (unidentified)
uh when read somewhere around 190 but exact number I won't be able to comment but somewhere around there
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Revenue for the quarter is 24 crores | ₹24 cr | ₹50.35 cr | Understated vs filing |
| Overall growth guidance 10-15% for the year | 12.5% | 11.8% | Matches filing |
| Export growth guidance 15-20% for the year | 17.5% | 11.8% | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.